A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/20 (2006.01) A61K 31/485 (2006.01) A61P 25/04 (2006.01)
Patent
CA 2652980
Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with alcohol. The fo.pi.nulations are useful for treating a patient suffering from a condition, e.g., pain. The formulations comprise at least one drug. In one embodiment, the drug is an opioid, e.g., oxymorphone.
Formulations robustes à libération prolongée, formes pharmaceutiques solides comprenant ces formulations, et procédés d'élaboration et d'utilisation de ces formulations et formes pharmaceutiques solides. La robustesse de la formulation à libération prolongée est liée à la taille de particule de la gomme hydrophile. Ce type de formulation résiste à la libération massive (chute de la dose) lorsqu'on l'ingère avec de l'alcool. Les formulations décrites sont utiles pour le traitement d'un patient qui souffre d'une affection, par exemple en cas de douleur. Les formulations renferment au moins un médicament. Selon une variante, le médicament est un opioïde, par exemple de l'oxymorphone.
Baichwal Anand R.
Fitzmaurice Kevin
Hein William
Howard-Sparks Michelle
Labudzinski Steve
Penwest Pharmaceuticals Co.
Smart & Biggar
LandOfFree
Robust sustained release formulations of oxymorphone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Robust sustained release formulations of oxymorphone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Robust sustained release formulations of oxymorphone will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1386896